Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology (NYSE American: MAIA) has strengthened its Scientific Advisory Board by appointing two leading HCC specialists, Dr. Claudia Fulgenzi and Dr. David J. Pinato. The appointments come as MAIA prepares for a Phase 2 clinical trial of its lead candidate ateganosine (THIO) in hepatocellular carcinoma (HCC).
The company expects to begin patient enrollment in the HCC trial by year-end, leveraging its 2022 FDA Orphan Drug Designation for ateganosine in HCC treatment, which could provide up to seven years of market exclusivity. Both appointees bring extensive expertise in liver cancer research and immunotherapy, with Dr. Pinato serving as Director of Developmental Cancer Therapeutics at Imperial College London and Dr. Fulgenzi specializing in immune-oncology at Imperial College London.
MAIA Biotechnology (NYSE: MAIA) has announced a private placement offering of 463,332 shares of common stock at $1.50 per share to accredited investors and a Company director. The offering includes warrants to purchase an equal number of shares at $1.71 per exercise price, exercisable after six months with a five-year term. The private placement is expected to close around May 29, 2025, with anticipated gross proceeds of approximately $695,000.
The company plans to use the proceeds to fund Step 1 of Part C of the Phase II THIO-101 trial and for working capital. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, and have not been registered under the Securities Act.
MAIA Biotechnology (NYSE: MAIA) announced the acceptance of their abstract for poster presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will showcase efficacy data from their Phase 2 THIO-101 clinical trial of ateganosine (THIO), a telomere targeting agent, in combination with cemiplimab for third-line immune checkpoint inhibitor-resistant advanced NSCLC.
The poster, titled "Phase 2 Study of Telomere-Targeting Agent THIO Sequenced With Cemiplimab in Third-Line Immune Checkpoint Inhibitor–Resistant Advanced NSCLC: Evaluation of Overall Survival," will be presented by Dr. Tomasz Jankowski on May 31, 2025, from 1:30 PM to 4:30 PM CDT in the Lung Cancer track. CEO Vlad Vitoc expressed confidence in ateganosine's potential to become a best-in-class anticancer treatment.
MAIA Biotechnology (NYSE: MAIA) has secured a $1.08 million private placement through the sale of 719,999 shares of common stock at $1.50 per share to accredited investors and company directors. The offering includes warrants to purchase one share of common stock at $2.05 per share, exercisable one year after issuance with a six-year term.
The private placement is expected to close around May 7, 2025. The proceeds will be used to fund the initiation of Part C of the Phase II THIO-101 trial and for working capital. Securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with director purchases made through the Company's 2021 Equity Incentive Plan.